Effects of Antimuscarinics on Cognition in Spinal Cord Injury

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective evaluation of the cognitive function of in-house patients suffering from an acute traumatic spinal cord injury before and three months after the initiation of antimuscarinic treatment.

The following hypothesis will be tested: Antimuscarinic treatment results in significantly worse cognitive test results three months after traumatic spinal cord injury compared to the pre-treatment results and the results of the control group.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swiss Paraplegic Centre Nottwil
• Treatments: Muscarinic Antagonists

Criteria

Inclusion Criteria:

• acute traumatic spinal cord injury

• primary rehabilitation / in-house patient

• 18-65 years of age

• treatment group: indication for antimuscarinic treatment (oxybutynin, tolterodine

• willingness and motivation to participate in study

Exclusion Criteria:

• lesion level above C4

• traumatic brain injury (initial Glasgow Coma Score < 13)

• pre-existing dementia

• pre-existing impaired cognitive function

• previous antimuscarinic treatment

• treatment group: antimuscarinic treatment other than oxybutynin, tolterodine

• acute psychologic disorders, diseases, schizophrenia

• alcohol abuse, consumption of illegal drugs (incl. marijuana)

• moderate to severe depression (Beck Depression Inventory Score > 18)

• moderate to severe pain (International Spinal Cord Injury Pain Basic Data Set)

• progressive disease

• tricyclic antidepressant

• color blindness, impaired sight, blindness

• insufficient German language skills

• no informed consent